Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies
thinkBiotech, 2004 264 pp. hardcover, $34.95 ISBN 0-9734676-2-2 | ISBN: 0-9734676-2-2
Biotechnology is widely acknowledged to be a great industry in which to work, for its combination of social benefits and potential financial rewards. It is constantly in the news—for both good reasons and bad—and is now mature enough in the public markets to merit its own indices and a legion of analysts that track stock performance for over 400 publicly traded companies. At the same time, biotechnology is perceived to be a strategic industry for many countries, states and regions because of its potential for high-tech job creation and competitive advantages in trade. Graduates from life science programs around the world now readily consider careers in biotechnology, and because of significant recent mergers and acquisitions among companies of all sizes, there is a pool of biotech workers who are often on the move. In addition, there are those in the biotech-related legal and financial industries, armchair observers and pundits, all of whom are fascinated by the biotech industry. It is to all these groups that Yali Friedman addresses his book, Building Biotechnology.
This is a preview of subscription content, access via your institution
